Title : Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.

Pub. Date : 2012 Jun 5

PMID : 22622860






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The number of gadolinium-enhancing T1 (T1-Gd) lesions was reduced in both teriflunomide groups, with relative risk reductions (RRRs) of 84.6% (p = 0.0005) and 82.8% (p < 0.0001) for 7 and 14 mg, respectively, compared with IFNbeta alone at 48 weeks. teriflunomide interferon beta 1 Homo sapiens